Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation

Study Overview
=================
Brief Summary
-----------------
Study is intended to evaluate the one-year safety and clinical status of patients treated for symptomatic uterine fibroids with the VizAblate Intrauterine-ultrasound guided radio frequency (RF) ablation system. Particular attention will be directed to recording safety outcomes including incidence of uterine cavity synechiae. In addition, information on quality of life will be collected. Overall study duration (first patient enrolled through last patient exit) will be comprised of approximately 12 months of patient enrollment up to 1 month for scheduling of treatment, and 12 months of follow-up, for a total duration of up to 25 months. Study duration for an individual patient, once enrolled, will be approximately 1 month for baseline observations and treatment scheduling, and 12 months for follow up after treatment for a total duration of approximately 13 months.

Detailed Description
-----------------
In this single-arm study, subjects who receive transcervical intrauterine-ultrasound guided RF ablation of symptomatic uterine fibroids with the VizAblate® System will be assessed with 3D pelvic sonography with contrast, hysteroscopy, and quality of life questionnaires. Overall study duration (first patient enrolled through last patient exit) will be comprised of approximately 12 months of patient enrollment up to 1 month for scheduling of treatment, and 12 months of follow-up, for a total duration of up to 25 months. Study duration for an individual patient, once enrolled, will be approximately 1 month for baseline observations and treatment scheduling, and 12 months for follow up after treatment for a total duration of approximately 13 months.

Official Title
-----------------
Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation

Conditions
-----------------
Menorrhagia, Leiomyoma, Uterine Fibroids, Uterine Fibroma, Uterine Neoplasms

Intervention / Treatment
-----------------
* Device: VizAblate System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 28 years of age or older Indication for transcervical treatment of uterine fibroids associated with menorrhagia Willingness to participate in the study, to attend all follow-up visits and undergo all study assessments, and to sign the informed consent form Presence of submucosal and/or intramural fibroids Exclusion Criteria: Pregnancy ≥40 years of age with desire for current or future fertility, unless the estimated risk/benefit ratio has been determined to be more favorable to future pregnancy than standard therapy Non-sterilized patients < 40 years of age, unless the estimated risk/benefit ratio has been determined to be more favorable to future pregnancy than standard therapy Active pelvic infection, known or suspected gynecologic malignancy or premalignant condition Presence of tubal implant for sterilization Previous pelvic irradiation Endometrial cavity length, including endocervical canal, < 4.5 cm Any abnormality of the vagina or uterine cavity that, in the judgment of the investigator obstructs access of the VizAblate handpiece to the endometrial cavity Presence of cardiac pacemaker or other active implant Post-menopausal

Ages Eligible for Study
-----------------
Minimum Age: 28 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| VizAblate treatment<br>VizAblate System with subject serving as her own control | Device: VizAblate System<br>* The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean percentage change in treated fibroid perfused volume |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fibroid total volume reduction |  | 12 months | 
| Incidence of Intrauterine adhesiogenesis | The cavity will be as classified per the European Society for Hysteroscopy (ESH) | 7 weeks | 
| Procedure Safety | Frequency and type of adverse events occurring on the day of the procedure | Day of procedure | 
| Long-term safety | Frequency and type of adverse events occurring post treatment through 12 months | 12 months | 
| Percentage reduction in the Symptom Severity Score sub scale of the Uterine Fibroid Symptom - Quality of Life questionnaire |  | 12 months | 
| Percentage increase in the Health Related Quality-of-Life (HRQL) sub scale of the Uterine Fibroid Symptom-Quality of Life questionnaire |  | 12 months | 
| Rate of surgical reintervention for menorrhagia |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Menorrhagia, Leiomyoma, Uterine Fibroids